Answers are grounded in this paper and cite their sources.
Soft tissue sarcomas (STS) are a heterogeneous group of mesenchymal malignancies comprising over 50 histological subtypes. Despite their rarity, these tumors are characterized by aggressive clinical behavior, high metastatic potential, and limited sensitivity to conventional systemic therapies. Accumulating evidence highlights the pivotal role of the tumor microenvironment in STS progression, prognosis, and treatment response. The composition of the immune infiltrate – including tumor-associated macrophages, T and B lymphocytes, and tertiary lymphoid structures – varies substantially across histological subtypes and determines both tumor biology and susceptibility to immunotherapy. The discovery of the prognostic and predictive significance of tertiary lymphoid structures and B-cell infiltration in STS has been one of the most important advances in the field. Immune checkpoint inhibitors have shown clinical activity in select subtypes, including undifferentiated pleomorphic sarcoma, angiosarcoma, and alveolar soft part sarcoma, although overall response rates remain modest. Combination strategies integrating immune checkpoint inhibitors with antiangiogenic agents, chemotherapy, or radiation therapy, as well as adoptive cellular therapies using engineered T-cell receptors, are opening new avenues for personalized treatment. This review systematizes current knowledge on the cellular and molecular composition of the STS microenvironment, its prognostic significance, and emerging therapeutic opportunities.
No takes yet. Share an insight, caveat, or question.
Makhachev et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: